Relationship Between Coronary Artery Calcium and Atherosclerosis Progression Among Patients With Suspected Coronary Artery Disease.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 05 2021
revised: 16 12 2021
accepted: 21 12 2021
entrez: 9 6 2022
pubmed: 10 6 2022
medline: 14 6 2022
Statut: ppublish

Résumé

Among symptomatic patients, it remains unclear whether a coronary artery calcium (CAC) score alone is sufficient or misses a sizeable burden and progressive risk associated with obstructive and nonobstructive atherosclerotic plaque. Among patients with low to high CAC scores, our aims were to quantify co-occurring obstructive and nonobstructive noncalcified plaque and serial progression of atherosclerotic plaque volume. A total of 698 symptomatic patients with suspected coronary artery disease (CAD) underwent serial coronary computed tomographic angiography (CTA) performed 3.5 to 4.0 years apart. Atherosclerotic plaque was quantified, including by compositional subgroups. Obstructive CAD was defined as ≥50% stenosis. Multivariate linear regression models were used to measure atherosclerotic plaque progression by CAC scores. Cox proportional hazard models estimated CAD event risk (median of 10.7 years of follow-up). Across baseline CAC scores from 0 to ≥400, total plaque volume ranged from 30.4 to 522.4 mm CAC imperfectly characterizes atherosclerotic disease burden, but its subgroups exhibit pathogenic patterns of early to advanced disease progression and stratify long-term prognostic risk.

Sections du résumé

BACKGROUND
Among symptomatic patients, it remains unclear whether a coronary artery calcium (CAC) score alone is sufficient or misses a sizeable burden and progressive risk associated with obstructive and nonobstructive atherosclerotic plaque.
OBJECTIVES
Among patients with low to high CAC scores, our aims were to quantify co-occurring obstructive and nonobstructive noncalcified plaque and serial progression of atherosclerotic plaque volume.
METHODS
A total of 698 symptomatic patients with suspected coronary artery disease (CAD) underwent serial coronary computed tomographic angiography (CTA) performed 3.5 to 4.0 years apart. Atherosclerotic plaque was quantified, including by compositional subgroups. Obstructive CAD was defined as ≥50% stenosis. Multivariate linear regression models were used to measure atherosclerotic plaque progression by CAC scores. Cox proportional hazard models estimated CAD event risk (median of 10.7 years of follow-up).
RESULTS
Across baseline CAC scores from 0 to ≥400, total plaque volume ranged from 30.4 to 522.4 mm
CONCLUSIONS
CAC imperfectly characterizes atherosclerotic disease burden, but its subgroups exhibit pathogenic patterns of early to advanced disease progression and stratify long-term prognostic risk.

Identifiants

pubmed: 35680215
pii: S1936-878X(22)00103-6
doi: 10.1016/j.jcmg.2021.12.015
pii:
doi:

Substances chimiques

Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1063-1074

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Partial funding was provided by a gift from the Dalio Foundation (New York, New York) and supported by the Leading Foreign Research Institute Recruitment Program through the National Research Foundation funded by the Ministry of Science and Information and Communications Technology of Korea (Grant number 2012027176). Dr Chinnaiyan is a medical advisor (unpaid) for Heartflow, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Emma J Hollenberg (EJ)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Emory University School of Medicine, Atlanta, Georgia, USA.

Fay Lin (F)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA.

Michael J Blaha (MJ)

Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Matthew J Budoff (MJ)

Department of Medicine, Lundquist Institute at Harbor UCLA Medical Center, Torrance, California, USA.

Inge J van den Hoogen (IJ)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Umberto Gianni (U)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA.

Yao Lu (Y)

Department of Healthcare Policy and Research, New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York, USA.

A Maxim Bax (AM)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA.

Alexander R van Rosendael (AR)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA; Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Sara W Tantawy (SW)

Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and Weill Cornell Medicine, New York, New York, USA.

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Filippo Cademartiri (F)

Cardiovascular Imaging Center, SDN IRCCS, Naples, Italy.

Kavitha Chinnaiyan (K)

Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan, USA.

Jung Hyun Choi (JH)

Pusan University Hospital, Busan, South Korea.

Edoardo Conte (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Pedro de Araújo Gonçalves (P)

UNICA, Unit of Cardiovascular Imaging, Hospital da Luz, Nova Medical School, Lisbon, Portugal.

Martin Hadamitzky (M)

Department of Radiology and Nuclear Medicine, German Heart Center, Munich, Germany.

Erica Maffei (E)

Department of Radiology, Area Vasta 1/ASUR Marche, Urbino, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Sanghoon Shin (S)

Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea.

Yong-Jin Kim (YJ)

Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul, South Korea.

Byoung Kwon Lee (BK)

Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Eun Ju Chun (EJ)

Seoul National University Bundang Hospital, Sungnam, South Korea.

Ji Min Sung (JM)

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul South Korea.

Alessia Gimelli (A)

Department of Imaging, Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Sang-Eun Lee (SE)

Yonsei-Cedars-Sinai Integrative Cardiovascular Imaging Research Center, Yonsei University College of Medicine, Yonsei University Health System, South Korea.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.

Daniel S Berman (DS)

Department of Imaging and Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.

Stephanie L Sellers (SL)

Department of Medicine and Radiology, University of British Columbia, Vancouver, BC, Canada.

Jonathon A Leipsic (JA)

Department of Medicine and Radiology, University of British Columbia, Vancouver, BC, Canada.

Ron Blankstein (R)

Division of Cardiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Jagat Narula (J)

Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, Zena and Michael A. Wiener Cardiovascular Institute, and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, New York, New York, USA.

Hyuk-Jae Chang (HJ)

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul South Korea.

Leslee J Shaw (LJ)

Icahn School of Medicine at Mount Sinai, Mount Sinai Heart, Zena and Michael A. Wiener Cardiovascular Institute, and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, New York, New York, USA. Electronic address: leslee.shaw@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH